Media.Player

PARP genomic variants conferring resistance and sensitization to chemotherapy under inhibition

Detailed Technology Description

None

*Abstract

BackgroundWhile chemotherapeutic agents are usually effective means to suppress cancer progression or reduce disease symptoms, in some cases nonresponsiveness, insufficient sensitivity or resistance to this treatment is observed. Many chemotherapeutic agents function through damaging DNA in tumor cells and therefore the natural DNA repair functions in these cells act against the effect of the chemotherapy. Because of its key role in the DNA repair, PARP1 is an important target for inhibitors.Technology DescriptionThe innovators developed a novel approach concerning genomic variants in PARP1 gene sequence. By identifying patients with this variant, it is possible to identify patients that will benefit from treatment with PARP1 inhibitors along with chemotherapy.ApplicationsTo determine which patients have PARP1 gene sequence so clinicians can see select either chemotherapy or chemotherapy in combination with PARP inhibitors for individual patient, so outcome of treatment benefits the patient.AdvantagesPatients may be treated with lower doses of the chemotherapeutic agentPatient may have less side-effects Development StatusIn vitro dataPatent StatusUS Provisional Application Filed

*Principal Investigator

Name: Irina Abecassis

Department: Med-Immunology

Name: Panagiotis Benos

Department: Med-Computational and Systems Biology

Name: Petr Pancoska, Research Associate Professor

Department: Dent Med-Oral Biology

Name: Marjorie Romkes, Associate Professor

Department: Med-Medicine

Name: Andrew Sedgewick

Department: Med-Computational and Systems Biology

Name: Hussein Tawbi

Department: Med-Medicine

Country/Region

USA